{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-24-000009","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.205373+00:00","generated_at":"2026-06-05T15:22:30.174095+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Krystal Biotech reports Q4 net product revenue of $42.1M from VYJUVEK; net income of $8.7M","bullets":["Net product revenue $42.1M in Q4 2023; $50.7M full year 2023; gross margin 93% in Q4.","FDA aligned on single-arm study to approve B-VEC eyedrops for ocular DEB in ~10 patients; study starts 2H 2024.","Cash & investments $594.1M at year-end; net income $8.7M in Q4 vs net loss of $32.1M in prior-year quarter.","First patient dosed in Phase 1 KB408 for AATD; FDA granted ODD. Interim data expected 2H 2024.","FY2024 non-GAAP R&D+SG&A guidance $150M-$175M."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-24-000009","json":"https://secwatch.observer/filing/0001711279-24-000009.json","markdown":"https://secwatch.observer/filing/0001711279-24-000009.md","text":"https://secwatch.observer/filing/0001711279-24-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000009/0001711279-24-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000009/krys-20240226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T15:22:30.174095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d41f034d9dc2e921575cfba521bb2a25a639c65b","claim":"Krystal Biotech, Inc. reported the quarter and year ended December 31, 2023 results: revenue $42.1M in 4Q and $50.7M for the year.","evidence_excerpt":"in such filing. --- EX-99.1 (EX-99.1) --- Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates • Net product revenue of $42.1M in 4Q and $50.7M for the year • New England Journal of Medicine publication of the use of B-VEC eyedrop formulation • Reached alignment with FDA to enable approval of B-VEC","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000009/0001711279-24-000009-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$42.1M in 4Q and $50.7M for the year"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}